Published on July 6, 2011
FOR IMMEDIATE RELEASE:
July 6, 2011
MEDIA CONTACT:
Eileen Sexton
(703) 837-3691
eileen.sexton@preventcancer.org
Study indicates that celecoxib may lower lung cancer development in former smokers
(Alexandria, Va.)—The Prevent Cancer Foundation is encouraged by the latest findings in the July issue of Cancer Prevention Research, an American Association for Cancer Research journal, reporting that celecoxib may prevent lung cancer in former smokers. The study, “Lung Cancer Chemoprevention with Celecoxib inFormer Smokers,” indicates celecoxib has significant bronchial health benefits that could potentially reverse the process that leads to lung cancer, the leading cancer killer of Americans.
The Foundation looks forward to the Phase III outcomes and the possibilities it could bring to millions. “These studies show significant promise and have the potential to save millions of lives by stopping cancer before it starts,” said Carolyn Aldige, President and Founder, Prevent Cancer Foundation, www.preventcancer.org. “For the nearly 90 million Americans who are either current or former smokers, this could mean the difference between life and death. The only answer for current smokers, of course, is to quit smoking all together.”
# # #
About The Prevent Cancer Foundation:
The mission of the Prevent Cancer Foundation is to save lives through cancer prevention and early detection. Founded in 1985, the Foundation has provided more than $125 million in support of cancer prevention and early detection research, education, advocacy and community outreach nationwide. For more information, please visit www.preventcancer.org.
